To determine whether more TNF inhibition may be associated with a higher frequency of psoriasis AEs, the nanomoles per recommended RA initial dose (nmols/(initial dose)) were calculated for each TNF inhibitor monotherapy cohort and compared with the respective cohort’s frequency of psoriasis reports (Table 6, Fig. 6). The gene discussed is TNF; the disease is rheumatoid arthritis.